Welcome to our dedicated page for CURANEX PHARMACEUTICALS news (Ticker: CURX), a resource for investors and traders seeking the latest updates and insights on CURANEX PHARMACEUTICALS stock.
Curanex Pharmaceuticals Inc. develops botanical drug candidates for serious diseases with unmet medical need. Company news centers on Phyto-N, its lead botanical therapeutic candidate, including preclinical toxicology work, IND preparation, pharmacokinetics and Chemistry, Manufacturing and Controls activities tied to inflammatory-disease development.
Recurring updates also cover the company’s expanded focus on cancer cachexia and advanced cancer supportive care, alongside its broader pipeline references to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease and gout. Other company developments include patient case reports, Scientific Advisory Board activity, capital-structure disclosures, governance matters, operating results and Nasdaq listing-compliance communications.
Curanex Pharmaceuticals (Nasdaq: CURX) engaged Strategic Investor Relations, LLC on October 22, 2025 to strengthen investor communications and visibility. The firm will support outreach, refine messaging, and highlight Curanex’s botanical drug pipeline targeting ulcerative colitis, atopic dermatitis, and gouty arthritis.
The company's lead Ulcerative Colitis candidate is on track for an IND submission in 2026, and management emphasized regulatory compliance with the FDA and a development approach informed by over 30 years of clinical evidence in China.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company, announced the full exercise of the over-allotment option by lead underwriter Dominari Securities LLC following its IPO. The underwriters purchased an additional 562,500 shares at $4.00 per share, raising an extra $2.25 million.
The total gross proceeds from the IPO now amount to $17.25 million through the issuance of 4,312,500 total shares. The offering was led by Dominari Securities LLC, with Pacific Century Securities and Revere Securities as co-underwriters. The registration statement became effective on August 12, 2025.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has successfully completed its Initial Public Offering (IPO). The company raised $15 million in gross proceeds through the offering of 3,750,000 shares at $4.00 per share.
Trading of CURX shares commenced on the Nasdaq Capital Market on August 26, 2025. The underwriters, led by Dominari Securities LLC, have a 45-day option to purchase up to 562,500 additional shares at the public offering price, less underwriting discounts and expenses.
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has announced the pricing of its initial public offering of 3,750,000 shares at $4.00 per share.
The IPO is expected to raise $15 million in gross proceeds before deducting underwriting costs. Trading will commence on August 26, 2025 on the Nasdaq Capital Market. Underwriters have a 45-day option to purchase up to 562,500 additional shares.
Proceeds will fund the development of their lead product Phyto-N for ulcerative colitis, conduct FDA-required toxicology studies, prepare an IND application, and provide working capital. Dominari Securities leads the underwriting, with Pacific Century Securities and Revere Securities as co-underwriters.